MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNA (miRNA) deregulation is linked to cancer drug resistance, particularly in malignant melanoma (MM).
• MiR-488-3p shows tumor-suppressive roles in other cancers, but its function in MM drug resistance is unclear.
• Understanding miR-488-3p's role is crucial for developing novel MM therapies.

Purpose of the Study:

• To investigate the expression and function of miR-488-3p in malignant melanoma drug resistance.
• To elucidate the molecular mechanisms by which miR-488-3p affects MM sensitivity to chemotherapy.
• To evaluate miR-488-3p as a potential therapeutic sensitizer in MM.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) and western blotting to assess miR-488-3p and PRKDC expression.
• Luciferase reporter assays to confirm direct targeting of PRKDC by miR-488-3p.
• In vitro and in vivo experiments involving ectopic miR-488-3p expression and PRKDC knockdown/overexpression.

Main Results:

• MiR-488-3p was significantly downregulated in MM clinical samples and cell lines.
• Ectopic miR-488-3p expression increased MM cell sensitivity to cisplatin (DDP) both in vitro and in vivo.
• PRKDC was identified as a direct target of miR-488-3p; PRKDC knockdown enhanced DDP sensitivity, while its overexpression partially reversed miR-488-3p's effect.

Conclusions:

• MiR-488-3p acts as a tumor suppressor and a drug resistance sensitizer in malignant melanoma.
• The miR-488-3p/PRKDC axis plays a critical role in regulating MM chemoresistance.
• MiR-488-3p represents a promising therapeutic target for overcoming drug resistance in MM.